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Urolithiasis is a common urologic disease that affects
approximately 10% of the population worldwide [1].
Uric acid is a frequent component of urinary stones
and affects calcium stone formation. The prevalence of
uric acid stones is estimated to be 5–10% of all urinary
stone diseases [2]. A correct diagnosis and understand-
ing of the pathophysiology of uric acid nephrolithia-
sis have important therapeutic implications. Thus, we
reviewed the current clinical pictures of uric acid stone
as well as the related literature.
MATERIALS AND METHODS
Between January 2004 and December 2005, a retrospec-
tive study was performed in three hospitals in sub-
tropical southern Taiwan. A total of 46 patients with
uric acid stones verified by stone analysis were identi-
fied. Clinical data, including age, sex, body mass index
(BMI), stone location, presentation of single or multiple
stones, pre-existing comorbidities (i.e. diabetes melli-
tus, hypertension, gout), serum creatinine and uric
acid levels, and urinary pH were collected. Stone
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Uric acid urolithiasis develops from various causes. To investigate the clinical and biochemical
presentation of patients with uric acid urolithiasis, a retrospective study was designed. A total of 46
cases were enrolled between January 2004 and December 2005. The compositions of the stones were
analyzed by infrared spectrophotometry. There were 39 males (84.8%) and seven females (15.2%),
with a mean age of 61.5 ± 10.6 years and mean body mass index (BMI) of 26.7 ± 3.1 kg/m2. The
stone location was kidney in 10 (21.7%), ureter in 22 (41.8%), and bladder in 14 (30.5%). Multiple
stones were diagnosed in 36 patients (78.3%). Pre-existing comorbidities included diabetes mellitus
in 11 patients (23.9%), hypertension in 23 (50%), gout in 13 (28.2%), and benign prostatic hyperplasia
in 14 (30.4%). Mean serum creatinine and uric acid was 1.6 ± 0.6 mg/dL and 7.6 ± 1.8 mg/dL,
respectively. There were 27 patients (58%) with creatinine > 1.4 mg/dL. The mean urinary pH
was 5.42 ± 0.46. Patients with uric acid urolithiasis were predominantly male, older, with higher
BMI, multiple stone presentation, with lower urinary pH, and hyperuricemia. Exacerbation of
the renal function should also be of concern because of the high proportion of patients with renal
insufficiency diagnosed in this study.
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composition was analyzed by Fourier transformed
infrared spectrophotometry.
RESULTS
There were 46 patients, 39 males (84.8%) and seven
females (15.2%), with a mean age of 61.5 ± 10.6 years
and mean BMI of 26.7 ± 3.1 kg/m2. The stone location
was kidney in 10 (21.7%), ureter in 22 (41.8%), and
bladder in 14 (30.5%). Multiple stone presentation
was diagnosed in 36 (78.3%). Pre-existing conditions
included diabetes mellitus in 11 patients (23.9%),
hypertension in 23 (50%), gout in 13 (28.2%), and
benign prostatic hyperplasia in 14 (30.4%). Mean
serum creatinine and uric acid levels were 1.6 ±
0.6 mg/dL and 7.6 ± 1.8 mg/dL, respectively. The
mean urinary pH was 5.42 ± 0.46.
DISCUSSION
The prevalence of uric acid urolithiasis varies in dif-
ferent geographical areas and countries, e.g. 5–10% in
the US, 17–25% in Germany, 4% in Sweden, and up to
40% in Israel. The apparent geographic variations
indicate that genetic, dietary, and environmental fac-
tors may have important roles in the formation of uric
acid stones [2].
Gout is an ancient disease and its association with
uric acid stones has long been recognized. Uric acid
stones are formed from dehydration, excessive sweat-
ing, intestinal alkali loss, and purine overload or
overproduction. Idiopathic uric acid nephrolithiasis
may also develop despite the absence of the above
causes. People with uric acid stones may have normo-
uricemia in some situations, since it is believed that
uric acid urolithiasis is due to defects in urinary acid-
ification and excretion of urates [3–5].
An increasing percentage of the population is
affected by obesity and the metabolic syndrome, a con-
dition that is metabolically characterized by insulin
resistance and clinically defined by abdominal obesity,
dyslipidemia, elevated blood pressure, and elevated
fasting glucose. It is reported that patients with recur-
rent uric acid stones manifest clinical and metabolic
abnormalities consistent with the metabolic syndrome
[4,6,7]. Lower urinary pH increases concentrations of
the sparingly soluble undissociated uric acid, which
directly promotes the formation of uric acid stones.
Because of the overlapping clinical features between
gouty diathesis and the metabolic syndrome, the rela-
tionship of the defective biologic activity of insulin and
urinary acidification has been studied. It is suggested
that the renal manifestation of insulin resistance may
be low urinary ammonium and pH. This defect can
result in increased risks of uric acid stone formation
despite normo-uricosuria [8,9].
Our data show that patients with uric acid uro-
lithiasis were mostly older males with high BMI,
multiple stone presentation, lower urinary pH, and
higher serum uric acid level. Acidic urine is a prereq-
uisite for uric acid stone formation and growth.
Management with urinary alkalization for stone disso-
lution and prevention of recurrence should be effective.
Low purine diet ingestion to decrease hyperuricemia
and lifestyle modification to reduce the incidence of
overweight or obesity can also be helpful. 
Furthermore, an exacerbation of renal function
should be of concern because a high proportion of
patients with renal insufficiency were noted in our
study. Some reports have investigated the significance
of hyperuricemia on the risk of developing end-stage
renal disease. Strategies for decreasing serum uric acid
levels may be recommended to prevent the progres-
sion of renal failure [10,11].
In conclusion, the profile of patients with uric acid
urolithiasis was male, older, and with higher BMI,
multiple stone presentation, lower urinary pH, and
higher serum uric acid. A high proportion of patients
with renal insufficiency was also diagnosed in this
study.
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